CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) shares gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $28.27, but opened at $22.05. CeriBell shares last traded at $27.6950, with a volume of 230,483 shares traded.
The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The firm had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the stock. TD Cowen lifted their price target on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. BTIG Research reissued a “buy” rating on shares of CeriBell in a report on Wednesday. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.25.
Insider Activity at CeriBell
In other news, VP David Foehr sold 9,255 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the transaction, the vice president owned 34,144 shares of the company’s stock, valued at approximately $827,992. The trade was a 21.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Xingjuan Chao sold 39,540 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $24.61, for a total transaction of $973,079.40. Following the transaction, the chief executive officer owned 767,191 shares of the company’s stock, valued at $18,880,570.51. This represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 179,792 shares of company stock valued at $4,444,748. Company insiders own 17.70% of the company’s stock.
Institutional Investors Weigh In On CeriBell
Several large investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in CeriBell during the 1st quarter valued at $27,000. Legal & General Group Plc acquired a new position in CeriBell during the 2nd quarter worth $53,000. State of Wyoming bought a new position in shares of CeriBell in the first quarter worth $62,000. Quantbot Technologies LP acquired a new position in shares of CeriBell during the second quarter valued at $112,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of CeriBell during the first quarter valued at $341,000.
CeriBell Price Performance
The business has a fifty day moving average price of $25.18 and a 200 day moving average price of $20.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 8.79. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -13.41 and a beta of 0.86.
CeriBell Company Profile
CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.
The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.
Featured Articles
- Five stocks we like better than CeriBell
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
